Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

SMC backs drug for skin condition

  • Comment
The Scottish Medicines Consortium has accepted imiquimod (Aldara) for the topical treatment of keratoses.

The drug is approved for restricted use for the topical treatment of clinically typical, non-hyperkeratotic, non-hypertrophic actinic keratoses on the face or scalp in immunocompetent adult patients – when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs